0L85 Stock Overview
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Sorrento Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.11 |
| 52 Week High | US$1.23 |
| 52 Week Low | US$0.022 |
| Beta | 2.1 |
| 11 Month Change | 149.43% |
| 3 Month Change | 7.32% |
| 1 Year Change | -89.81% |
| 33 Year Change | -98.49% |
| 5 Year Change | -96.73% |
| Change since IPO | -98.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0L85 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -29.0% | 0.3% | 2.2% |
| 1Y | -89.8% | -18.3% | 8.0% |
Return vs Industry: 0L85 underperformed the UK Biotechs industry which returned -27% over the past year.
Return vs Market: 0L85 underperformed the UK Market which returned -1.4% over the past year.
Price Volatility
| 0L85 volatility | |
|---|---|
| 0L85 Average Weekly Movement | 92.9% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0L85's share price has been volatile over the past 3 months.
Volatility Over Time: 0L85's weekly volatility has increased from 54% to 93% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 949 | Henry Ji | www.sorrentotherapeutics.com |
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.
Sorrento Therapeutics, Inc. Fundamentals Summary
| 0L85 fundamental statistics | |
|---|---|
| Market cap | US$66.28m |
| Earnings (TTM) | -US$548.00m |
| Revenue (TTM) | US$64.27m |
1.0x
P/S Ratio-0.1x
P/E RatioIs 0L85 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0L85 income statement (TTM) | |
|---|---|
| Revenue | US$64.27m |
| Cost of Revenue | US$221.74m |
| Gross Profit | -US$157.47m |
| Other Expenses | US$390.53m |
| Earnings | -US$548.00m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | -245.01% |
| Net Profit Margin | -852.65% |
| Debt/Equity Ratio | -71.8% |
How did 0L85 perform over the long term?
See historical performance and comparison